Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879522 | 0.87 | LMNA (0.62) | LMNAELANEMGLLMEN1KMT2A | |
| SCHEMBL13879544 | 0.84 | LMNA (0.58) | LMNAMGLLMEN1KMT2APOLB | |
| SCHEMBL11866914 | 0.82 | LMNA (0.47) | LMNAELANEMGLLMEN1KMT2A | |
| SCHEMBL13879422 | 0.82 | LMNA (0.57) | LMNAELANEMGLLMEN1KMT2A | |
| SCHEMBL13879504 | 0.75 | ELANE (0.47) | LMNAELANEMGLLMEN1KMT2A | |
| SCHEMBL13879488 | 0.73 | MAPT (0.50) | LMNAMGLLMEN1KMT2AHSD17B10 | |
| SCHEMBL13879463 | 0.72 | LMNA (0.52) | LMNAMEN1KMT2AALOX15TSHR | |
| SCHEMBL25069088 | 0.71 | LMNA (0.62) | LMNAMGLLMEN1KMT2AALOX15 | |
| SCHEMBL9733457 | 0.71 | ELANE (0.43) | LMNAELANEMGLLMEN1KMT2A | |
| SCHEMBL13879457 | 0.71 | LMNA (0.55) | LMNAMGLLMEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | LMNA 2024/4885ELANE 364/4885MGLL 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.